
...

By Jenna Sundel
News Reporter
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
The U.S. Department of Health and Human Services and the Food and Drug Administration announced major reform on Tuesday that requires pharmaceutical companies to include full safety warnings in direct-to-consumer ads on television and digital platforms.
The policy ends a loophole dating to 1997 that allowed drug companies to note information such as full contraindications and common precautions on webpages and toll-free numbers.
Why It Matters
Until 1997, pharmaceutical companies were required to disclose full contraindications, boxed warnings and common precautions in ads. The FDA then allowed companies to use a "major-risk statement" and direct viewers to a website, toll-free number or print insert for more information.
Read More on Politics
HHS said the "simplistic" pharmaceutical ads "distorted physician prescribing habits and patient decisions."

...
What To Know
President Donald Trump issued a memo on Tuesday addressing "misleading" direct-to-consumer prescription drug ads.
"My Administration will ensure that the current regulatory framework for drug advertising results in fair, balanced, and complete information for American consumers," Trump said in the memo.
The FDA said it is issuing roughly 100 cease-and-desist letters to companies with "deceptive" ads.
HHS said research showed direct-to-consumer advertising had driven about 31 percent of the rise in U.S. drug spending since 1997.
The U.S. and New Zealand are the only countries that allow direct-to-consumer prescription drug advertising.
What People Are Saying
Health and Human Services Secretary Robert F. Kennedy Jr., in a statement: "Pharmaceutical ads hooked this country on prescription drugs. We will shut down that pipeline of deception and require drug companies to disclose all critical safety facts in their advertising. Only radical transparency will break the cycle of overmedicalization that drives America's chronic disease epidemic."
FDA Commissioner Marty Makary, in a statement: "For far too long, the FDA has permitted misleading drug advertisements, distorting the doctor-patient relationship and creating increased demand for medications regardless of clinical appropriateness. Drug companies spend up to 25% of their budget on advertising. Those billions of dollars would be better spent on lowering drug prices for everyday Americans."
Alex Schriver, spokesperson for drug industry lobbying group Pharmaceutical Research and Manufacturers of America (PhRMA), told The Hill: "Truthful and non-misleading DTC advertising is protected under the First Amendment and has documented evidence of advancing patient awareness and engagement. PhRMA member companies are committed to responsible advertising, and we look forward to learning more details about the policy changes announced today."
What Happens Next
The FDA is sending out thousands of letters warning pharmaceutical companies to "remove any noncompliant advertising and bring all promotional communications into compliance."
Do you have a story that Newsweek should be covering? Do you have any questions about this story? Contact LiveNews@newsweek.com.
View 0 Comments
Submit Correction
View Editorial & AI Guidelines